Exome sequencing identifies rare damaging variants in the ATP8B4 and ABCA1 genes as novel risk factors for Alzheimer’s Disease
Abstract
The genetic component of Alzheimer’s disease (AD) has been mainly assessed using Genome Wide Association Studies (GWAS), which do not capture the risk contributed by rare variants. Here, we compared the gene-based burden of rare damaging variants in exome sequencing data from 32,558 individuals —16,036 AD cases and 16,522 controls— in a two-stage analysis. Next to known genes TREM2, SORL1 and ABCA7, we observed a significant association of rare, predicted damaging variants in ATP8B4 and ABCA1 with AD risk, and a suggestive association in ADAM10 and SRC. Next to these genes, our analysis highlighted RIN3, CLU, ZCWPW1 and ACE as potential causal genes in AD-GWAS loci. Rare damaging variants in these genes, and in particular loss-of-function variants, have a large effect on AD-risk, and they are enriched in early onset AD cases. The newly identified AD-associated genes provide additional evidence for a major role for APP-processing, Aβ-aggregation and microglial function in AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Please see acknowledgment section on page 101 of the Supplemental material submitted with this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB body from the institutes of all respective studies that contributed to this sample have approved this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵16 ADNI consortium; see supplemental authors
Data Availability
Data will be made available upon journal publication.
Subject Area
- Addiction Medicine (324)
- Allergy and Immunology (632)
- Anesthesia (168)
- Cardiovascular Medicine (2397)
- Dermatology (207)
- Emergency Medicine (381)
- Epidemiology (11789)
- Forensic Medicine (10)
- Gastroenterology (705)
- Genetic and Genomic Medicine (3763)
- Geriatric Medicine (350)
- Health Economics (637)
- Health Informatics (2406)
- Health Policy (937)
- Hematology (342)
- HIV/AIDS (785)
- Medical Education (367)
- Medical Ethics (105)
- Nephrology (401)
- Neurology (3521)
- Nursing (199)
- Nutrition (528)
- Oncology (1830)
- Ophthalmology (538)
- Orthopedics (220)
- Otolaryngology (287)
- Pain Medicine (234)
- Palliative Medicine (66)
- Pathology (447)
- Pediatrics (1036)
- Primary Care Research (424)
- Public and Global Health (6175)
- Radiology and Imaging (1288)
- Respiratory Medicine (831)
- Rheumatology (380)
- Sports Medicine (324)
- Surgery (403)
- Toxicology (50)
- Transplantation (172)
- Urology (147)